Nigerian biotech startup Syndicate Bio has joined forces with SOPHiA GENETICS, a leading cloud-native software company in the healthcare sector, to pioneer comprehensive genomic profiling and liquid biopsy services throughout Africa. This groundbreaking partnership marks a significant milestone, making these advanced medical technologies widely accessible to patients across the continent.
Founded in September by Dr. Abasi Ene-Obong, along with Dr. Jumi Popoola and Estelle Dogbo, Syndicate Bio is committed to advancing precision medicine in Africa through strategic collaborations with governments, pharmaceutical firms, academia, and other key stakeholders. By leveraging these partnerships, Syndicate Bio aims to enhance local healthcare outcomes, while also contributing valuable data to global health initiatives and expediting drug discovery and development processes.
The company recently announced a strategic partnership with the National Institute for Cancer Research and Treatment (NICRAT) to launch the Cancer Genome Nigeria project. By integrating SOPHiA GENETICS’ cutting-edge technology, Syndicate Bio seeks to build upon existing collaborations with institutions like Memorial Sloan Kettering Cancer Center (MSK) to promote health equity on a global scale.
Dr. Ene-Obong emphasized the significance of this partnership in advancing cancer treatment and research in Africa, particularly in Nigeria. By incorporating next-generation sequencing and liquid biopsy technologies, Syndicate Bio aims to revolutionize oncology care on the continent and improve patient outcomes. The collaboration with SOPHiA GENETICS underscores their commitment to leveraging AI-driven solutions for predictive genetic testing, non-invasive cancer analysis, and precision medicine, ultimately transforming the landscape of cancer care across Africa.
